Stocktoria
Alaunos Therapeutics, Inc. TCRT
Alaunos Therapeutics, Inc. (TCRT) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $5,000 at a -83520.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TCRT | Alaunos Therapeutics, Inc. | 2/9 | — | — | — |
| ASBP | Aspire Biopharma Holdings, Inc. | 2/9 | — | — | — |
| GNLX | GENELUX Corp | 2/9 | — | — | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | 1/9 | -8.96 | — | -100% |
| XCUR | EXICURE, INC. | 1/9 | — | — | — |
| VTVT | vTv Therapeutics Inc. | 3/9 | -5.57 | — | — |
| VKTX | Viking Therapeutics, Inc. | 1/9 | 7.05 | — | — |
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.
FAQ
Is TCRT financially healthy?
Alaunos Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does TCRT pay a dividend?
No, Alaunos Therapeutics, Inc. does not currently pay a dividend.
How profitable is TCRT?
In FY2025, Alaunos Therapeutics, Inc. had a net margin of -83520.0% and a return on equity of -194.0%.
Is TCRT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Alaunos Therapeutics, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.